Navamedic ASA: National approvals of Flexilev® in OraFID® granted across all Nordic countries
"We are excited to have received the last approvals, paving the way for our go-to-market launch in the Nordic region," said
Flexilev® in OraFID® ensures precise and personalized treatment tailored to individual Parkinson's Patient needs. Medications with a narrow therapeutic window can benefit from hyper-fractionation, which involves administering smaller, more frequent doses.
OraFID® is a unique, patented, fully mechanical medical device that dispenses precise quantities of minitablets with just a few of twists of the hands.
The launch in the Nordic markets is still anticipated in
For further information, please contact:
Mobile: +47 951 78 680 Mobile: +47 917 62 842
E-mail: kathrine@navamedic.com E-mail: lars.hjarrand@navamedic.com
About
What sets us apart is our deep-rooted commitment to understanding the needs and requirements of the countries where we are present. Our local insight and competence enable us to understand the specific needs of each country where we operate and ultimately to gain market access. This makes us a preferred partner for international companies expanding their footprint across the Nordics and Benelux regions, through either in-licensing or out-licensing.
For more information, please visit Navamedic.com
This information is subject to the disclosure requirements pursuant to section 5 -12 of the Norwegian Securities Trading Act.
This information was brought to you by Cision http://news.cision.com
View original content:https://www.prnewswire.co.uk/news-releases/navamedic-asa-national-approvals-of-flexilev-in-orafid-granted-across-all-nordic-countries-302528798.html
